source
- FDA updates guidance for generic makers of top GLP-1 weight-loss drugsThe FDA has released a revised draft guidance aimed at companies that want to develop generic versions of leading weight-loss medications. The update focuses on products such as Eli Lilly's Zepbou…
- Claris Bio raises $118M Series B and appoints new CEO to advance eye-drug for limbal stem cell deficiencyClaris Bio, a New Jersey biotechnology company, announced a $118 million Series B financing round co-led by Samsara BioCapital and Catalio Capital Management, with participation from Sofinnova Inve…